Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis unveils positive data for Tasigna

Novartis unveils positive data for Tasigna

7th December 2010

Novartis has published phase III data revealing that its new drug Tasigna (nilotinib) compares favourably with Glivec (imatinib) for the treatment of chronic myeloid leukaemia (CML).

In the 24-month analysis, first-line treatment with Tasigna at 300 mg twice daily was found to slow disease progression when compared with the standard approved Glivec dose of 400 mg once daily.

The study focused on adult patients with newly-diagnosed Philadelphia chromosome-positive CML in chronic phase.

It also revealed that Tasigna induced a deeper and more durable complete cytogenetic response and major molecular response than treatment with Glivec.

"We are encouraged by the ongoing clinical development of Tasigna as a new treatment," said Herve Hoppenot, president of Novartis Oncology.

He added that Glivec "revolutionised the treatment of Philadelphia chromosome-positive CML" when it was approved in 2001.

The Committee for Medicinal Products for Human Use (CHMP) recommended Tasigna for European Commission approval for the first-line indication in September.ADNFCR-8000103-ID-800275964-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.